Abstract

Case Report

New era of liver transplantation for HIV-HCV Co-infected patients: A case report

Konstantinos A Zorbas*, Sunil S Karhadkar, Kwan N Lau, Andreas Karachristos and Antonio Di Carlo

Published: 14 November, 2017 | Volume 1 - Issue 1 | Pages: 072-076

Morbidity and mortality of HIV-infected patients have been improved over the last decades with the advent of combined antiretroviral therapy. As a result, other comorbidities such as chronic kidney and chronic liver diseases have emerged in the HIV population. A considerable percentage of end-stage liver disease (ESLD) in HIV population is attributed to hepatitis C co-infection and reactivation, and a growing need for solid organ transplantation has emerged among those patients. On the other hand, several studies on liver transplantations of patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) have shown discouraging results both in patient and graft survival rates. As a result, HIV-HCV co-infection has been considered a relative contraindication for liver transplantation. Thankfully, new drugs for HCV treatment have been discovered, acting direct on viral replication of HCV and they have changed the whole clinical course of HCV/HIV co-infected liver transplant recipients. Our case illustrates the long-term efficacy and safety of the new combination of Sofosbuvir/Ledipasvir in HCV/HIV co-infected liver transplant recipients.

Read Full Article HTML DOI: 10.29328/journal.ascr.1001012 Cite this Article Read Full Article PDF

Keywords:

Liver Transplantation; HIV; HCV; Immunosuppression; Direct Acting Antivirals; Ledipasvir/Sofosbuvir

References

 

  1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338: 853-860. Ref.: https://goo.gl/NKoaxq
  2. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014; 384: 241-248. Ref.: https://goo.gl/RbEuFa
  3. Bica I, McGovern B, Dhar R, Stone D, McGowan K, et al., Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001; 32: 492-497. Ref.: https://goo.gl/JCgaT2
  4. Sulkowski MS. Hepatitis C virus infection in HIV-infected patients. Curr HIV/AIDS Rep. 2004; 1: 128-135. Ref.: https://goo.gl/UPnMpF
  5. Kardashian AA, Price JC. Hepatitis C virus-HIV-coinfected patients and liver transplantation. Curr Opin Organ Transplant. 2015; 20: 276-285. Ref.: https://goo.gl/BZ2dbo
  6. de Vera ME, Dvorchik I, Tom K, Eghtesad B, Thai N, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant. 2006; 6: 2983-2993. Ref.: https://goo.gl/Zkvzq2
  7. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis. 2011; 52: 889-900. Ref.: https://goo.gl/jtRmH8
  8. Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct- acting antiviral agents. J Viral Hepat. 2012; 19: 449-464. Ref.: https://goo.gl/DxaFKS
  9. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370: 1483-1493. Ref.: https://goo.gl/JEj6LZ
  10. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014; 370: 1889-1898. Ref.: https://goo.gl/NFgYh2
  11. Frassetto LA, Browne M, Cheng A, Wolfe AR, Ronald ME, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant. 2007; 7: 2816-2820. Ref.: https://goo.gl/2GCzb6
  12. Wu Z, Bensinger SJ, Zhang J, Chen C, Yuan X, et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med. 2004; 10: 87-92. Ref.: https://goo.gl/SvpVXw
  13. Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N, et al. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol. 2012; 11: 179-185. Ref.: https://goo.gl/CsY2yS
  14. Grant JL, Hawkins C, Brooks H, Frank J Palella, Sean WP Koppe, et al. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection. AIDS. 2016; 30: 93-98. Ref.: https://goo.gl/yYx5PH
  15. Campos-Varela I, Stephanie S, Eliana Z Agudelo, Laurie C, Norah AT. Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients. Liver Transpl. 2015; 21: 272-274. Ref.: https://goo.gl/Wz1Nwn
  16. Alkhouri N, Singh G, Carey WD, Fung JJ, Zein NN, et al. The successful use of telaprevir to treat hepatitis C recurrence after liver transplantation in an HIV co-infected patient. Transplantation. 2014; 97: 14-15. Ref.: https://goo.gl/s17rVev

Figures:

Figure 1

Figure 1

Similar Articles

  • New era of liver transplantation for HIV-HCV Co-infected patients: A case report
    Konstantinos A Zorbas*, Sunil S Karhadkar, Kwan N Lau, Andreas Karachristos and Antonio Di Carlo Konstantinos A Zorbas*,Sunil S Karhadkar,Kwan N Lau,Andreas Karachristos,Antonio Di Carlo. New era of liver transplantation for HIV-HCV Co-infected patients: A case report. . 2017 doi: 10.29328/journal.ascr.1001012; 1: 072-076
  • Actinomycosis of the appendix
    Lucas Wheatley*, Michael Lonne, James Bennnet and Bhavik Patel Lucas Wheatley*,Michael Lonne,James Bennnet,Bhavik Patel. Actinomycosis of the appendix. . 2018 doi: 10.29328/journal.ascr.1001020; 2: 029-030

Recently Viewed

Read More

Most Viewed

Read More